In particular, increased intratumoral MDSCs infiltration was found to correlate with circulating VEGF levels in several tumor types including HCC [70]; in addition preclinical studies demonstrated that sunitinib [71] and sorafenib [72] could decrease MDSC levels in spleen, bone marrow and tumor. Here, VEGFA is linked to neoplasm.